Handelen 10x Genomics, Inc. - TXG CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Spread | 0.14 | ||||||||
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.024874% | ||||||||
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.002651% | ||||||||
Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
Min. verhandelde hoeveelheid | 1 | ||||||||
Valuta | USD | ||||||||
Marge | 20% | ||||||||
Effectenbeurs | United States of America | ||||||||
Handelscommissie | 0% |
*Information provided by Capital.com
Prev. Close* | 51.97 |
Open* | 53.18 |
1-Jaarlijkse Verandering* | -28.68% |
Dagelijks bereik* | 53.18 - 56.09 |
52 wekelijks bereik | 23.81-83.34 |
Weekgemiddelde volume (10 dagen) | 754.85K |
Gemiddeld volume (3 maanden) | 21.21M |
Marktkapitalisatie | 6.00B |
P/E Ratio | -100.00K |
Uitstaande Aandelen | 115.36M |
Omzet | 516.41M |
EPS | -1.46 |
Dividend (opbrengst %) | N/A |
Beta | 1.74 |
Volgende inkomsten datum | May 2, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
---|---|---|---|---|---|---|
Mar 31, 2023 | 55.73 | 3.30 | 6.29% | 52.43 | 56.16 | 52.01 |
Mar 30, 2023 | 51.97 | 0.76 | 1.48% | 51.21 | 52.32 | 51.07 |
Mar 29, 2023 | 50.69 | 1.41 | 2.86% | 49.28 | 50.98 | 49.00 |
Mar 28, 2023 | 48.81 | -0.45 | -0.91% | 49.26 | 49.42 | 48.27 |
Mar 27, 2023 | 49.70 | -0.68 | -1.35% | 50.38 | 51.52 | 49.29 |
Mar 24, 2023 | 50.12 | 2.16 | 4.50% | 47.96 | 50.30 | 47.65 |
Mar 23, 2023 | 48.97 | 0.03 | 0.06% | 48.94 | 51.49 | 48.48 |
Mar 22, 2023 | 48.69 | -1.39 | -2.78% | 50.08 | 51.08 | 48.61 |
Mar 21, 2023 | 50.03 | 1.83 | 3.80% | 48.20 | 50.25 | 47.91 |
Mar 20, 2023 | 47.76 | 0.30 | 0.63% | 47.46 | 48.56 | 46.76 |
Mar 17, 2023 | 48.08 | -1.09 | -2.22% | 49.17 | 49.71 | 47.66 |
Mar 16, 2023 | 50.25 | 2.49 | 5.21% | 47.76 | 50.90 | 47.60 |
Mar 15, 2023 | 48.54 | 1.45 | 3.08% | 47.09 | 49.32 | 47.08 |
Mar 14, 2023 | 48.63 | 0.07 | 0.14% | 48.56 | 49.52 | 48.06 |
Mar 13, 2023 | 47.44 | 3.47 | 7.89% | 43.97 | 49.32 | 43.97 |
Mar 10, 2023 | 44.93 | -1.55 | -3.33% | 46.48 | 46.49 | 43.15 |
Mar 9, 2023 | 47.00 | -1.65 | -3.39% | 48.65 | 49.98 | 46.93 |
Mar 8, 2023 | 48.95 | 1.16 | 2.43% | 47.79 | 49.49 | 47.24 |
Mar 7, 2023 | 48.16 | 0.10 | 0.21% | 48.06 | 49.75 | 47.48 |
Mar 6, 2023 | 48.39 | -2.30 | -4.54% | 50.69 | 50.80 | 48.13 |
10x Genomics, Inc. Events
Tijd (UTC) (UTC) | Land | Evenement |
---|---|---|
No events scheduled |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Totale inkomsten | 516.409 | 490.49 | 298.845 | 245.893 | 146.313 |
Inkomsten | 516.409 | 490.49 | 298.845 | 245.893 | 146.313 |
Kosten van opbrengsten, totaal | 120.386 | 74.091 | 58.468 | 61.033 | 28.661 |
Brutowinst | 396.023 | 416.399 | 240.377 | 184.86 | 117.652 |
Totale bedrijfskosten | 684.353 | 542.743 | 834.508 | 276.466 | 257.077 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 298.3 | 257.56 | 199.726 | 130.834 | 87.936 |
Onderzoek & Ontwikkeling | 265.667 | 211.752 | 570.923 | 83.097 | 109.9 |
Other Operating Expenses, Total | 0 | -0.66 | 1.27 | 1.502 | 30.58 |
Bedrijfsresultaat | -167.944 | -52.253 | -535.663 | -30.573 | -110.764 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | 6.171 | -0.66 | -0.15 | -0.274 | -1.385 |
Overige, Netto | -0.198 | -0.802 | 1.337 | -0.186 | -0.249 |
Netto inkomen voor belastingen | -161.971 | -53.715 | -534.476 | -31.033 | -112.398 |
Netto inkomen na belastingen | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Netto inkomen voor extra. Posten | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Totale buitengewone posten | |||||
Netto inkomen | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Verwaterd Netto Inkomen | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Verwaterd Gewogen Gemiddelde Aandelen | 113.859 | 110.348 | 101.152 | 96.2416 | 93.8497 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -1.45795 | -0.52763 | -5.36552 | -0.32471 | -1.19857 |
Verwaterde Genormaliseerde Winst per Aandeel | -1.45795 | -0.52763 | -5.33904 | -0.32471 | -1.19857 |
Ongebruikelijke uitgaven (inkomsten) | 0 | 0 | 4.121 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Totale inkomsten | 156.232 | 131.072 | 114.609 | 114.496 | 143.53 |
Inkomsten | 156.232 | 131.072 | 114.609 | 114.496 | 143.53 |
Kosten van opbrengsten, totaal | 36.827 | 30.377 | 27.704 | 25.478 | 27.598 |
Brutowinst | 119.405 | 100.695 | 86.905 | 89.018 | 115.932 |
Totale bedrijfskosten | 179.328 | 171.068 | 177.726 | 156.231 | 159.36 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 78.887 | 73.401 | 79.337 | 66.675 | 69.877 |
Onderzoek & Ontwikkeling | 63.614 | 67.29 | 70.685 | 64.078 | 61.885 |
Ongebruikelijke uitgaven (inkomsten) | 0 | 0 | |||
Other Operating Expenses, Total | 0 | 0 | 0 | 0 | |
Bedrijfsresultaat | -23.096 | -39.996 | -63.117 | -41.735 | -15.83 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | 2.69 | 1.911 | 1.129 | 0.441 | -0.168 |
Overige, Netto | 3.995 | -1.95 | -1.843 | -0.4 | 0.005 |
Netto inkomen voor belastingen | -16.411 | -40.035 | -63.831 | -41.694 | -15.993 |
Netto inkomen na belastingen | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Netto inkomen voor extra. Posten | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Netto inkomen | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Verwaterd Netto Inkomen | -17.215 | -41.914 | -64.458 | -42.413 | -18.449 |
Verwaterd Gewogen Gemiddelde Aandelen | 114.767 | 114.112 | 113.575 | 112.966 | 111.913 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.15 | -0.3673 | -0.56754 | -0.37545 | -0.16485 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Verwaterde Genormaliseerde Winst per Aandeel | -0.15 | -0.3673 | -0.56754 | -0.37545 | -0.16485 |
- Jaarlijks
- Per kwartaal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Totaal vlottende activa | 747.591 | 774.366 | 480.84 | 106.236 | 68.107 |
Geldmiddelen en kortetermijnbeleggingen | 587.447 | 663.603 | 424.166 | 65.08 | 47.857 |
Geldmiddelen & Equivalenten | 587.447 | 663.603 | 424.166 | 65.08 | 47.857 |
Totale Vorderingen, Netto | 85.254 | 51.208 | 33.371 | 29.566 | 13.341 |
Accounts Receivable - Trade, Net | 85.254 | 51.208 | 33.371 | 28.088 | 13.341 |
Total Inventory | 59.966 | 29.959 | 15.27 | 8.57 | 4.838 |
Prepaid Expenses | 13.896 | 13.029 | 8.033 | 3.02 | 2.071 |
Total Assets | 1018.83 | 929.341 | 605.923 | 124.31 | 75.609 |
Property/Plant/Equipment, Total - Net | 230.41 | 119.823 | 48.821 | 11.127 | 6.925 |
Property/Plant/Equipment, Total - Gross | 279.431 | 150.325 | 67.876 | 25.21 | 17.958 |
Accumulated Depreciation, Total | -49.021 | -30.502 | -19.055 | -14.083 | -11.033 |
Other Long Term Assets, Total | 10.917 | 12.798 | 76.262 | 6.947 | 0.577 |
Total Current Liabilities | 110.357 | 118.126 | 63.049 | 32.362 | 22.141 |
Accounts Payable | 17.351 | 4.709 | 13.028 | 8.792 | 5.443 |
Accrued Expenses | 75.821 | 92.326 | 30.035 | 12.118 | 8.959 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 9.882 | 4.187 | 4.224 | |
Other Current Liabilities, Total | 17.185 | 21.091 | 10.104 | 7.265 | 3.515 |
Total Liabilities | 201.258 | 190.269 | 185.84 | 101.053 | 29.704 |
Total Long Term Debt | 0 | 0 | 19.837 | 25.489 | 6.335 |
Long Term Debt | 0 | 19.837 | 25.489 | 6.335 | |
Other Liabilities, Total | 90.901 | 72.143 | 102.954 | 43.202 | 1.228 |
Total Equity | 817.568 | 739.072 | 420.083 | 23.257 | 45.905 |
Redeemable Preferred Stock | 0 | 243.244 | 158.414 | ||
Common Stock | 0.002 | 0.002 | 0.002 | 0.001 | 0.001 |
Additional Paid-In Capital | 1680.86 | 1544.22 | 682.494 | 11.165 | 6.136 |
Retained Earnings (Accumulated Deficit) | -863.321 | -805.098 | -262.367 | -231.116 | -118.631 |
Other Equity, Total | 0.022 | -0.05 | -0.046 | -0.037 | -0.015 |
Total Liabilities & Shareholders’ Equity | 1018.83 | 929.341 | 605.923 | 124.31 | 75.609 |
Total Common Shares Outstanding | 112.515 | 108.486 | 96.2416 | 93.8497 | 93.8497 |
Other Current Assets, Total | 1.028 | 16.567 | |||
Intangibles, Net | 25.397 | 22.354 | |||
Goodwill, Net | 4.511 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Totaal vlottende activa | 697.335 | 747.591 | 744.104 | 757.174 | 745.716 |
Geldmiddelen en kortetermijnbeleggingen | 539.323 | 587.447 | 600.44 | 621.958 | 617.195 |
Geldmiddelen & Equivalenten | 312.487 | 587.447 | 600.44 | 621.958 | 617.195 |
Totale Vorderingen, Netto | 76.526 | 85.254 | 78.43 | 59.68 | 57.408 |
Accounts Receivable - Trade, Net | 76.526 | 85.254 | 78.43 | 59.68 | 57.408 |
Total Inventory | 63.697 | 59.966 | 51.141 | 44.087 | 38.507 |
Prepaid Expenses | 17.762 | 13.896 | 14.065 | 13.298 | 14.442 |
Other Current Assets, Total | 0.027 | 1.028 | 0.028 | 18.151 | 18.164 |
Total Assets | 1003.25 | 1018.83 | 990.572 | 977.579 | 954.033 |
Property/Plant/Equipment, Total - Net | 265.88 | 230.41 | 203.304 | 176.454 | 163.666 |
Property/Plant/Equipment, Total - Gross | 279.431 | 247.698 | 215.665 | 198.415 | |
Accumulated Depreciation, Total | -49.021 | -44.394 | -39.211 | -34.749 | |
Goodwill, Net | 4.511 | 4.511 | 4.511 | 4.511 | 4.511 |
Intangibles, Net | 24.764 | 25.397 | 26.041 | 26.693 | 27.342 |
Other Long Term Assets, Total | 10.761 | 10.917 | 12.612 | 12.747 | 12.798 |
Total Current Liabilities | 94.446 | 110.357 | 100.375 | 113.126 | 120.549 |
Accounts Payable | 18.956 | 17.351 | 17.037 | 16.181 | 15.578 |
Accrued Expenses | 59.913 | 75.821 | 69.92 | 85.598 | 95.307 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 15.577 | 17.185 | 13.418 | 11.347 | 9.664 |
Total Liabilities | 196.566 | 201.258 | 190.351 | 192.993 | 201.573 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | 0 | ||||
Other Liabilities, Total | 102.12 | 90.901 | 89.976 | 79.867 | 81.024 |
Total Equity | 806.685 | 817.568 | 800.221 | 784.586 | 752.46 |
Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Additional Paid-In Capital | 1714.86 | 1680.86 | 1644.9 | 1612.23 | 1569.06 |
Retained Earnings (Accumulated Deficit) | -905.734 | -863.321 | -844.872 | -827.701 | -816.649 |
Other Equity, Total | -2.443 | 0.022 | 0.194 | 0.058 | 0.048 |
Total Liabilities & Shareholders’ Equity | 1003.25 | 1018.83 | 990.572 | 977.579 | 954.033 |
Total Common Shares Outstanding | 113.276 | 112.515 | 111.537 | 110.74 | 109.589 |
Korte Termijn Investeringen | 226.836 |
- Jaarlijks
- Per kwartaal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Netto-inkomen/Beginsaldo | -58.223 | -542.731 | -31.251 | -112.485 | -18.762 |
Geldmiddelen uit Operationele Activiteiten | -21.373 | -217.898 | 34.627 | -76.409 | -10.699 |
Geldmiddelen uit Operationele Activiteiten | 21.118 | 14.012 | 7.066 | 3.905 | 4.305 |
Niet-Geldelijke Posten | 103.177 | 361.202 | 14.048 | 4.156 | 1.81 |
Cash Taxes Paid | 8.66 | 0.28 | -0.022 | -0.006 | 0 |
Contant Betaalde Rente | 1.222 | 1.67 | 2.25 | 1.824 | 0.658 |
Veranderingen in het Operationeel Kapitaal | -87.445 | -50.381 | 44.764 | 28.015 | 1.948 |
Geldmiddelen uit Investeringsactiviteiten | -106.729 | -38.394 | -42.767 | -6.709 | -3.756 |
Kapitaaluitgaven | -101.278 | -38.394 | -42.767 | -6.709 | -3.756 |
Geldmiddelen uit Financieringsactiviteiten | 35.297 | 468.906 | 414.59 | 105.367 | 20.583 |
Financiering van Cash Flow Posten | -5.028 | -5.848 | 0 | 0 | |
Uitgifte (Aflossing) van aandelen, netto | 40.325 | 506.01 | 414.59 | 86.628 | 20.976 |
Uitgifte (Aflossing) van Schulden, Netto | 0 | -31.256 | 0 | 18.739 | -0.393 |
Wisselkoerseffecten | 0.234 | -0.463 | -0.045 | -0.018 | -0.014 |
Nettowijziging in Geldmiddelen | -92.571 | 212.151 | 406.405 | 22.231 | 6.114 |
Overige Cash Flow investeringsposten, Totaal | -5.451 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -42.413 | -58.223 | -39.774 | -22.603 | -11.551 |
Cash From Operating Activities | -20.802 | -21.373 | -27.178 | -0.962 | -4.082 |
Cash From Operating Activities | 6.191 | 21.118 | 15.337 | 9.641 | 4.752 |
Non-Cash Items | 28.014 | 103.177 | 74.717 | 47.188 | 17.922 |
Cash Taxes Paid | 2.9 | 8.66 | 8.318 | 7.838 | 6.822 |
Cash Interest Paid | 0.841 | 1.222 | 1.222 | 1.222 | 1.222 |
Changes in Working Capital | -12.594 | -87.445 | -77.458 | -35.188 | -15.205 |
Cash From Investing Activities | -257.558 | -106.729 | -79.111 | -58.884 | -44.316 |
Capital Expenditures | -28.136 | -101.278 | -73.66 | -53.433 | -38.865 |
Other Investing Cash Flow Items, Total | -229.422 | -5.451 | -5.451 | -5.451 | -5.451 |
Cash From Financing Activities | 2.417 | 35.297 | 26.394 | 19.711 | 3.518 |
Financing Cash Flow Items | -5.409 | -5.028 | -5.028 | -5.028 | -5.028 |
Issuance (Retirement) of Stock, Net | 7.826 | 40.325 | 31.422 | 24.739 | 8.546 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0 | |
Foreign Exchange Effects | -0.018 | 0.234 | 0.316 | 0.199 | 0.193 |
Net Change in Cash | -275.961 | -92.571 | -79.579 | -39.936 | -44.687 |
Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
---|---|---|---|---|---|---|
Morgan Stanley Investment Management Inc. (US) | Investment Advisor/Hedge Fund | 9.4813 | 9210082 | -415196 | 2022-12-31 | LOW |
Baillie Gifford & Co. | Investment Advisor | 8.8556 | 8602235 | 158847 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.6523 | 8404774 | 145652 | 2022-12-31 | LOW |
Paladin Capital Management, LLC | Investment Advisor | 8.3511 | 8112208 | 0 | 2022-03-31 | |
ARK Investment Management LLC | Investment Advisor | 4.4437 | 4316567 | -260247 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.3422 | 4217954 | 207975 | 2022-12-31 | LOW |
Sands Capital Management, LLC | Investment Advisor | 3.3012 | 3206783 | -184394 | 2022-12-31 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 3.2549 | 3161803 | -518131 | 2022-12-31 | LOW |
SRS Investment Management, LLC | Hedge Fund | 3.0939 | 3005427 | 0 | 2022-12-31 | LOW |
Generation Investment Management LLP | Investment Advisor/Hedge Fund | 2.6231 | 2548100 | -57577 | 2022-12-31 | LOW |
Nikko Asset Management Co., Ltd. | Investment Advisor/Hedge Fund | 2.2421 | 2177988 | -29270 | 2022-12-31 | LOW |
Credit Suisse Asset Management | Investment Advisor/Hedge Fund | 2.1979 | 2135038 | -17833 | 2022-12-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.018 | 1960300 | -337642 | 2022-12-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 1.507 | 1463901 | 1108820 | 2022-12-31 | HIGH |
Brown Capital Management, LLC | Investment Advisor | 1.4964 | 1453630 | -161463 | 2022-12-31 | LOW |
Foresite Capital Management, LLC | Private Equity | 1.3985 | 1358528 | -1145000 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.3854 | 1345749 | -18168 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.3601 | 1321234 | 63324 | 2022-12-31 | LOW |
Millennium Management LLC | Hedge Fund | 1.2491 | 1213394 | 999487 | 2022-12-31 | HIGH |
JP Morgan Asset Management | Investment Advisor | 1.2158 | 1180996 | 27291 | 2022-12-31 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group500K+
Handelaren
92K+
Actieve klanten per maand
$53M+
Maandelijks beleggingsvolume
$30M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
10x Genomics, Inc. Company profile
Over 10x Genomics, Inc.
10x Genomics, Inc. is een biowetenschappelijk technologiebedrijf. De geïntegreerde oplossingen van het bedrijf omvatten instrumenten, verbruiksgoederen en software voor de analyse van biologische systemen. De producten omvatten Chromium Single Cell Gene Expression, Single Cell Immune Profiling, Single Cell assay for transposase accessible chromatin (ATAC) + Gene Expression, Single Cell ATAC, Spatial Gene Expression, Spatial Multiomics, en Targeted Gene Expression. De instrumenten omvatten de Chromium X Series, Chromium Connect en Chromium Controller. Zijn technologie Next GEM-technologie, die chips en compatibele reagentia omvat, die worden aangeboden voor de productportefeuille met één cel. Zijn portefeuille van verbruiksgoederen omvat microfluïdische chips, draagglaasjes, reagentia en andere verbruiksgoederen voor zowel zijn Visium- als Chromium-oplossingen. De toepassingen van het bedrijf omvatten geclusterde regelmatige interspaced short palindromic repeats (CRISPR) screening, multiomische cytometrie en het in kaart brengen van immuunreceptoren.
Industry: | Laboratory Diagnostic & Testing Substances |
6230 Stoneridge Mall Road
PLEASANTON
CALIFORNIA 94588
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 500.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen